Dehydrogenase

Inhibitory Selectivity

Isoform-specific Inhibitors

ALDH1A Selective

Dehydrogenase Products

All (37) Dehydrogenase Inhibitors (36) Dehydrogenase Agonists (1) New Dehydrogenase Products

Catalog No.	Information	Product Use Citations	Product Validations
S7185	AGI-5198 AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.	Proc Natl Acad Sci U S A, 2020, 5;117(18):9964-9972 Cancer Discov, 2020, CD-20-0226 Oncol Lett, 2020, 19(2):1322-1330	AGI-5198 restored p53 expression in HCT116 cells harboring IDH1 R132H mutant. HCT116 cells were infected with control lentivirus or lentivirus expressing Flag-WT IDH1 or IDH1-R132H. At 48 hr post-infection, cells were treated with or without 1.5 μM AGI-5198 for 2 days, followed by treating with 2.5 M DOX (or not) for another 9 hr in the presence of AGI-5198, as indicated.
S8000	Tenovin-1 Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also an inhibitor of dihydroorotate dehydrogenase (DHODH).	J Pharm Biomed Anal, 2021, 201:114121 J Transl Med, 2019, 17(1):76 Sci Rep, 2019, 9(1):1897	The SIRT1 inhibitor (tenovin-1) partially blocked the protective effect of γ-man in L02 cells. The effect of tenovin-1 on expression and acetylation level of PGC-1α (B) in L02 cells treated with or without γ-man.
S2987^New	4-Methyl-2-oxovaleric acid 4-Methyl-2-oxovaleric acid (Ketoleucine, 4-MOV, KIC, 4-Methyl-2-oxopentanoic acid, alpha-Ketoisocaproic acid, alpha-ketoisocaproate, 2-Oxoisohexanoate) is released by Astrocytes to neurons and can be reaminated by aminotransferase to leucine. 4-Methyl-2-oxovaleric acid reduces the rate of protein degradation in skeletal muscle. 4-Methyl-2-oxovaleric acid acts as an uncoupler of oxidative phosphorylation (OXPHOS) and as a metabolic inhibitor possibly through its inhibitory effect on alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase complex, OGDC) activity.
S3993	Ethyl Vanillate Ethyl vanillin (Bourbonal, Ethylprotal), a vanillin analog, is a flavouring agent and a fungicidal agent that exhibits strong antioxidant activity. Ethyl Vanillate inhibits 17β-HSD2 with an IC50 1.3 µM.
S6749	ASP-9521 ASP-9521 is a selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5).
S9776^New	AG-636 AG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity.
S4929^New	Enasidenib Mesylate Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
S3565^New	Brequinar Sodium Brequinar Sodium (Bipenquinate, BRQ, DUP-785, NSC 368390) is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of ~20 nM and triggers differentiation in the ER-HoxA9, U937, and THP1 cells with ED50 of ~1 μM.
S3574^New	IDH-305 IDH-305 (Compound 13) is an orally available, mutant-selective and brain-penetrant inhibitor of isocitrate dehydrogenase 1 (IDH1) that targets IDH1(R132) mutation with IC50 of 27 nM, 28 nM and 6.14 μM for IDH1^R132H, IDH1^R132C and IDH1^WT, respectively.
S9783^New	6-Aminonicotinamide 6-Aminonicotinamide (6AN) is an antimetabolite used to inhibit the NADPH-producing pentose phosphate pathway (PPP) in many cellular systems, making them more susceptible to oxidative stress. 6-Aminonicotinamide is a competitive inhibitor of NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) with Ki of 0.46 μM.
S9721^New	ASLAN003 ASLAN003 (LAS 186323) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity. ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional program in acute myeloid leukemia (AML) cells via activation of AP-1 transcription factors.	bioRxiv, 2021, 10.1101/2021.06.28.450163
S0718	AG-120 (racemic) AG-120 (racemic), the racemic mixture of AG-120, is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity.
S8382	ML390 ML390 is a human DHODH inhibitor with an IC50 of 0.56 μM and induces differentiation in acute myeloid leukemia.
S0522	CM10 CM10 is a potent and selective inhibitor of aldehyde dehydrogenase 1A family (ALDH1A) with IC50 of 1700 nM, 740 nM and 640 nM for ALDH1A1, ALDH1A2 and ALDH1A3, respectively. CM10 exhibits anti-cancer activity.
S8847	BAY 2402234 BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 1.2 nM.	bioRxiv, 2021, 10.1101/2021.06.28.450163
S0764	AKR1C1-IN-1 AKR1C1-IN-1 is a potent and selective inhibitor of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 4 nM, 87 nM, 4.2 μM and 18.2 μM for AKR1C1, AKR1C2, AKR1C3 and AKR1C4, respectively.
S4900	Tenovin-6 Tenovin-6 is a small molecule activator of p53 transcriptional activity and inhibits dihydroorotate dehydrogenase (DHODH). Tenovin-6 is also an inhibitor of SirT1 and SirT2.	Front Immunol, 2021, 12:685523 Biomed Pharmacother, 2020, 125:109948 J Cell Sci, 2019, 132(6)
S7900	SW033291 SW033291 is a selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) with IC50 and K_i^app of 1.5 nM and 0.1 nM, respectively.	J Clin Invest, 2020, 131554 Nat Commun, 2019, 10(1):181
S7241	AGI-6780 AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.	Oncogene, 2021, 10.1038/s41388-021-01968-2 Blood, 2018, 10.1182/blood-2018-05-850826 Theranostics, 2018, 8(15):4050-4061	Western blot of KMM-1 and NCI-H929 cells, UT, treated with DMSO, AGI-6780 (KMM-1: 5 μM; NCI-H929: 10 μM), CFZ (KMM-1: 5 nM; NCI-H929: 2.5 nM), or a combination of the 2 drugs. Cell lysates were immunoblotted using the indicated antibodies 24 hours posttreatment. Vinculin protein expression was included for protein loading normalization.
S7941	NCT-501 NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.
S9617	G6PDi-1 G6PDi-1 is an effective inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PDi-1 depletes NADPH and decreases inflammatory cytokine production.
S6675	(R)-GNE-140 (R)-GNE-140 is a selective inhibitor of the LDHA and LDHB with IC50s of 3 nM and 5 nM, respectively. The R enantiomer of GNE-140 is 18-fold more potent than S enantiomer.
S9645	CBR-5884 CBR-5884 is a selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and was selectively toxic to cancer cell lines with high serine biosynthetic activity.
S8405	RRx-001 RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. RRx-001 triggers apoptosis and exhibits anticancer activity.	Cell Mol Immunol, 2021, 18(6):1425-1436 Front Immunol, 2021, 12:718779
S2303	Gossypol Acetate Gossypol Acetate (Gossypol Acetic acid, Pogosin, AT101) is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes such as lactate dehydrogenase, NAD-linked enzymes.	Molecules, 2021, 26(5)1210 Mol Med Rep, 2021, 23(1)40 Biomed Pharmacother, 2019, 115:108860	16h after seeding HMLE RAS cells were exposed to 5 uM or 10 uM Gossypol in the presence or absence of Cisplatin for 16h. Afterwards, cells were harvested and lysates were analyzed for apoptosis by western blotting. Actin staining was used as loading control, while LC3a/b staining was used as indicator for autophagy. Accumulation of LC3a/b II indicates autophagy. Non-treated and DMSO-treated cells were used as control. Arrows are indicating the intended staining. For Bcl-xL: * indicates deamidated protein, # indicates unmodified protein. n=1.
S3652	3-Nitropropionic acid 3-Nitropropionic acid (β-Nitropropionic Acid, 3-NP) is an irreversible inhibitor of mitochondrial respiratory Complex II succinate dehydrogenase, resulting in energy depletion through disruption of the electron transport chain.	Front Immunol, 2021, 12:618501
S6852	Gossypol Gossypol (BL 193) is an orally-active polyphenol isolated from cotton seeds and roots. Gossypol is a potent inhibitor of 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase with IC50 of 3.33 μM and 0.52 μM in cell-free assay, respectively. Gossypol also inhibits the binding of BH3 peptide to Bcl protein with IC50 of 0.4 μM and 10 μM for Bcl-XL and Bcl-2, respectively. Gossypol induces apoptosis and cell growth inhibition in various cancer cells.	Mol Med Rep, 2021, 23(1)40 J Biol Chem, 2015, 290(34):20841-55
S8619	NCT-503 NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor with the IC50 value of 2.5 μM. It is inactive against a panel of other dehydrogenases and shows minimal cross-reactivity in a panel of 168 GPCRs.	Elife, 2020, 9e56749
S6689	Merimepodib Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro.Merimepodib is an immunosuppressive agent.
S8949	Olutasidenib (FT-2102) Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H, IDH1-R132C, respectively.
S8590	GSK 2837808A GSK2837808A is a selective LDHA (lactate dehydrogenase A) inhibitor with IC50 of 2.6 nM and 43 nM for hLDHA and hLDHB, respectively.
S8881	DS-1001b (DS 1001) DS-1001b is an oral selective inhibitor of mutant IDH1 R132X with potential antineoplastic activity and is designed to penetrate the blood-brain barrier.
S0209	BVT 2733 BVT 2733, a new small molecule, is a non-steroidal, isoform-selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
S5425	Phenylglyoxal hydrate Phenylglyoxal (1-Phenylethanedione) is a potent inhibitor of mitochondrial aldehyde dehydrogenase. It reacts with arginine residues in purified Hageman factor (HF, Factor XII) and causes inhibition of its coagulant properties.
S8530	BAY 1436032 BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). It is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displays potent inhibition of 2-HG release (nanomolar range) in patient derived and engineered cell lines expressing different IDH1 mutants.	Haematologica, 2020, 2 pii: haematol
S6626	Brequinar (DUP785) Brequinar (DUP785, NSC 368390) is an inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of ∼20 nM in vitro.	bioRxiv, 2021, 10.1101/2021.06.28.450163
S5800	Alda 1 Alda 1 is an ALDH2 agonist that activates catalysis for both wild-type ALDH2 (ALDH21) and ALDH22.

Catalog No.	Information	Product Use Citations	Product Validations
S7185	AGI-5198 AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.	Proc Natl Acad Sci U S A, 2020, 5;117(18):9964-9972 Cancer Discov, 2020, CD-20-0226 Oncol Lett, 2020, 19(2):1322-1330	AGI-5198 restored p53 expression in HCT116 cells harboring IDH1 R132H mutant. HCT116 cells were infected with control lentivirus or lentivirus expressing Flag-WT IDH1 or IDH1-R132H. At 48 hr post-infection, cells were treated with or without 1.5 μM AGI-5198 for 2 days, followed by treating with 2.5 M DOX (or not) for another 9 hr in the presence of AGI-5198, as indicated.
S8000	Tenovin-1 Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also an inhibitor of dihydroorotate dehydrogenase (DHODH).	J Pharm Biomed Anal, 2021, 201:114121 J Transl Med, 2019, 17(1):76 Sci Rep, 2019, 9(1):1897	The SIRT1 inhibitor (tenovin-1) partially blocked the protective effect of γ-man in L02 cells. The effect of tenovin-1 on expression and acetylation level of PGC-1α (B) in L02 cells treated with or without γ-man.
S2987^New	4-Methyl-2-oxovaleric acid 4-Methyl-2-oxovaleric acid (Ketoleucine, 4-MOV, KIC, 4-Methyl-2-oxopentanoic acid, alpha-Ketoisocaproic acid, alpha-ketoisocaproate, 2-Oxoisohexanoate) is released by Astrocytes to neurons and can be reaminated by aminotransferase to leucine. 4-Methyl-2-oxovaleric acid reduces the rate of protein degradation in skeletal muscle. 4-Methyl-2-oxovaleric acid acts as an uncoupler of oxidative phosphorylation (OXPHOS) and as a metabolic inhibitor possibly through its inhibitory effect on alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase complex, OGDC) activity.
S3993	Ethyl Vanillate Ethyl vanillin (Bourbonal, Ethylprotal), a vanillin analog, is a flavouring agent and a fungicidal agent that exhibits strong antioxidant activity. Ethyl Vanillate inhibits 17β-HSD2 with an IC50 1.3 µM.
S6749	ASP-9521 ASP-9521 is a selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5).
S9776^New	AG-636 AG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity.
S4929^New	Enasidenib Mesylate Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
S3565^New	Brequinar Sodium Brequinar Sodium (Bipenquinate, BRQ, DUP-785, NSC 368390) is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of ~20 nM and triggers differentiation in the ER-HoxA9, U937, and THP1 cells with ED50 of ~1 μM.
S3574^New	IDH-305 IDH-305 (Compound 13) is an orally available, mutant-selective and brain-penetrant inhibitor of isocitrate dehydrogenase 1 (IDH1) that targets IDH1(R132) mutation with IC50 of 27 nM, 28 nM and 6.14 μM for IDH1^R132H, IDH1^R132C and IDH1^WT, respectively.
S9783^New	6-Aminonicotinamide 6-Aminonicotinamide (6AN) is an antimetabolite used to inhibit the NADPH-producing pentose phosphate pathway (PPP) in many cellular systems, making them more susceptible to oxidative stress. 6-Aminonicotinamide is a competitive inhibitor of NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) with Ki of 0.46 μM.
S9721^New	ASLAN003 ASLAN003 (LAS 186323) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity. ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional program in acute myeloid leukemia (AML) cells via activation of AP-1 transcription factors.	bioRxiv, 2021, 10.1101/2021.06.28.450163
S0718	AG-120 (racemic) AG-120 (racemic), the racemic mixture of AG-120, is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity.
S8382	ML390 ML390 is a human DHODH inhibitor with an IC50 of 0.56 μM and induces differentiation in acute myeloid leukemia.
S0522	CM10 CM10 is a potent and selective inhibitor of aldehyde dehydrogenase 1A family (ALDH1A) with IC50 of 1700 nM, 740 nM and 640 nM for ALDH1A1, ALDH1A2 and ALDH1A3, respectively. CM10 exhibits anti-cancer activity.
S8847	BAY 2402234 BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 1.2 nM.	bioRxiv, 2021, 10.1101/2021.06.28.450163
S0764	AKR1C1-IN-1 AKR1C1-IN-1 is a potent and selective inhibitor of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 4 nM, 87 nM, 4.2 μM and 18.2 μM for AKR1C1, AKR1C2, AKR1C3 and AKR1C4, respectively.
S4900	Tenovin-6 Tenovin-6 is a small molecule activator of p53 transcriptional activity and inhibits dihydroorotate dehydrogenase (DHODH). Tenovin-6 is also an inhibitor of SirT1 and SirT2.	Front Immunol, 2021, 12:685523 Biomed Pharmacother, 2020, 125:109948 J Cell Sci, 2019, 132(6)
S7900	SW033291 SW033291 is a selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) with IC50 and K_i^app of 1.5 nM and 0.1 nM, respectively.	J Clin Invest, 2020, 131554 Nat Commun, 2019, 10(1):181
S7241	AGI-6780 AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.	Oncogene, 2021, 10.1038/s41388-021-01968-2 Blood, 2018, 10.1182/blood-2018-05-850826 Theranostics, 2018, 8(15):4050-4061	Western blot of KMM-1 and NCI-H929 cells, UT, treated with DMSO, AGI-6780 (KMM-1: 5 μM; NCI-H929: 10 μM), CFZ (KMM-1: 5 nM; NCI-H929: 2.5 nM), or a combination of the 2 drugs. Cell lysates were immunoblotted using the indicated antibodies 24 hours posttreatment. Vinculin protein expression was included for protein loading normalization.
S7941	NCT-501 NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.
S9617	G6PDi-1 G6PDi-1 is an effective inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PDi-1 depletes NADPH and decreases inflammatory cytokine production.
S6675	(R)-GNE-140 (R)-GNE-140 is a selective inhibitor of the LDHA and LDHB with IC50s of 3 nM and 5 nM, respectively. The R enantiomer of GNE-140 is 18-fold more potent than S enantiomer.
S9645	CBR-5884 CBR-5884 is a selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and was selectively toxic to cancer cell lines with high serine biosynthetic activity.
S8405	RRx-001 RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. RRx-001 triggers apoptosis and exhibits anticancer activity.	Cell Mol Immunol, 2021, 18(6):1425-1436 Front Immunol, 2021, 12:718779
S2303	Gossypol Acetate Gossypol Acetate (Gossypol Acetic acid, Pogosin, AT101) is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes such as lactate dehydrogenase, NAD-linked enzymes.	Molecules, 2021, 26(5)1210 Mol Med Rep, 2021, 23(1)40 Biomed Pharmacother, 2019, 115:108860	16h after seeding HMLE RAS cells were exposed to 5 uM or 10 uM Gossypol in the presence or absence of Cisplatin for 16h. Afterwards, cells were harvested and lysates were analyzed for apoptosis by western blotting. Actin staining was used as loading control, while LC3a/b staining was used as indicator for autophagy. Accumulation of LC3a/b II indicates autophagy. Non-treated and DMSO-treated cells were used as control. Arrows are indicating the intended staining. For Bcl-xL: * indicates deamidated protein, # indicates unmodified protein. n=1.
S3652	3-Nitropropionic acid 3-Nitropropionic acid (β-Nitropropionic Acid, 3-NP) is an irreversible inhibitor of mitochondrial respiratory Complex II succinate dehydrogenase, resulting in energy depletion through disruption of the electron transport chain.	Front Immunol, 2021, 12:618501
S6852	Gossypol Gossypol (BL 193) is an orally-active polyphenol isolated from cotton seeds and roots. Gossypol is a potent inhibitor of 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase with IC50 of 3.33 μM and 0.52 μM in cell-free assay, respectively. Gossypol also inhibits the binding of BH3 peptide to Bcl protein with IC50 of 0.4 μM and 10 μM for Bcl-XL and Bcl-2, respectively. Gossypol induces apoptosis and cell growth inhibition in various cancer cells.	Mol Med Rep, 2021, 23(1)40 J Biol Chem, 2015, 290(34):20841-55
S8619	NCT-503 NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor with the IC50 value of 2.5 μM. It is inactive against a panel of other dehydrogenases and shows minimal cross-reactivity in a panel of 168 GPCRs.	Elife, 2020, 9e56749
S6689	Merimepodib Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro.Merimepodib is an immunosuppressive agent.
S8949	Olutasidenib (FT-2102) Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H, IDH1-R132C, respectively.
S8590	GSK 2837808A GSK2837808A is a selective LDHA (lactate dehydrogenase A) inhibitor with IC50 of 2.6 nM and 43 nM for hLDHA and hLDHB, respectively.
S8881	DS-1001b (DS 1001) DS-1001b is an oral selective inhibitor of mutant IDH1 R132X with potential antineoplastic activity and is designed to penetrate the blood-brain barrier.
S0209	BVT 2733 BVT 2733, a new small molecule, is a non-steroidal, isoform-selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
S5425	Phenylglyoxal hydrate Phenylglyoxal (1-Phenylethanedione) is a potent inhibitor of mitochondrial aldehyde dehydrogenase. It reacts with arginine residues in purified Hageman factor (HF, Factor XII) and causes inhibition of its coagulant properties.
S8530	BAY 1436032 BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). It is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displays potent inhibition of 2-HG release (nanomolar range) in patient derived and engineered cell lines expressing different IDH1 mutants.	Haematologica, 2020, 2 pii: haematol
S6626	Brequinar (DUP785) Brequinar (DUP785, NSC 368390) is an inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of ∼20 nM in vitro.	bioRxiv, 2021, 10.1101/2021.06.28.450163